drugset / Trial / NCT01168921
Phase II Eltrombopag in Chronic Lymphocytic Leukemia (CLL)
NaSingle-groupOpen-labelTreatment
Summary
The goal of this clinical research study is to learn if eltrombopag can help to increase the number of platelets in patients with CLL. The safety of this drug will also be studied.
Timeline
- Start
- 2010-11-03
- Primary completion
- 2022-03-07
- Completion
- 2022-03-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Eltrombopag | Small molecule | 75 mg | Oral |